Skip to main content
. 2012 Dec 10;31(3):314–320. doi: 10.1200/JCO.2012.42.4101

Fig 3.

Fig 3.

CONSORT diagram illustrating patient flow on Southwest Oncology Group protocol S0016. AE, adverse event; CHOP-R, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy with rituximab; CHOP-RIT, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy followed by tositumomab/131I-tositumomab radioimmunotherapy.